56355-62-5

Basic information

• Product Name: METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE
• Synonyms: METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE;Ethyl 2-(2-bromo-5-methylthiazol-4-yl)acetate;Ethyl2-bromo-5-methyl-1,3-thiazole-4-carboxylate
• CAS NO: 56355-62-5
• Molecular Formula: C₇H₈BrNO₂S
• Molecular Weight: 250.11292
• Mol File: 56355-62-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE(56355-62-5)
• EPA Substance Registry System: METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE(56355-62-5)

Safety Data

• Hazardous Substances Data: 56355-62-5(Hazardous Substances Data)

Usage

General Description

Methyl (2-bromo-5-methyl-1,3-thiazol-4-yl)acetate is a chemical compound with the molecular formula C7H8BrNO2S. It is a thiazole derivative, which is a type of heterocyclic organic compound containing a five-membered ring with three carbon atoms, one nitrogen atom, and one sulfur atom. METHYL (2-BROMO-5-METHYL-1,3-THIAZOL-4-YL)ACETATE is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. Its specific properties and uses may vary depending on the context and industry in which it is employed.

Upstream product

• 72054-60-5 2-amino-5-methylthiazole-4-carboxylic acid ethyl ester 
• 57332-84-0 3-bromo-2-oxo-butyric acid ethyl ester 
• 15933-07-0 Ethyl 2-oxobutanoate 

Downstream Products

• 1187836-86-7 (2-bromo-5-methyl-1,3-thiazol-4-yl)methanol 
• 1204747-43-2 C₂₁H₁₇N₃O₂S 

Relevant articles and documents

Design and synthesis of novel triazole derivatives containing γ-lactam as potential antifungal agents

A series of novel triazole derivatives containing γ-lactam were designed and synthesized, and their structures were confirmed by 1H NMR, 13C NMR and HRMS. The in vitro antifungal activities of the target compounds were evaluated. The results showed that all of the compounds exhibited stronger activity against the six clinically important fungi tested than fluconazole. 3D and 3E showed comparative activity against the fungi tested except for Candida glabrata and Aspergillus fumigatus as voriconazole. In addition, the docking model for 2A and CYP51 was investigated.

HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.